Please login to the form below
T-DM1
This page shows the latest T-DM1 news and features for those working in and with pharma, biotech and healthcare.
Immunotherapy and future directions in oncology
Those dendritic cells can activate cytotoxic T-cells which, after replicating, track and eradicate cancer cells. ... Kadcyla (trastuzumab emtansine, Genentech of Roche) targets HER2 receptors present in breast cancer and delivers an anti-microtubule
Latest news
-
EU backs Roche’s Kadcyla in breast cancer
Expectations are high for the Kadcyla, which is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin with ImmunoGen's DM1, a cytotoxic payload designed to boost its
-
Roche's Herceptin follow-up cleared in US
Roche's Herceptin follow-up cleared in US. FDA approval for Kadcyla (formerly T-DM1) in breast cancer. ... The FDA has given the go-ahead to Kadcyla, formerly known as T-DM1, as a therapy for patients with HER2-positive, late-stage metastatic breast
-
Product updates from Japan
pylori", according to the partners. Chugai Pharmaceutical has filed for approval of trastuzumab emtansine (T-DM1) - originally developed by Roche/Genentech as a follow-up to their Herceptin (trastuzumab) blockbuster - for ... Chugai has commercialisation
-
Roche delivers solid sales gain in 2012
Perjeta has been tipped as a future blockbuster, as has Herceptin follow-up trastuzumab emtansine ( T-DM1), which is filed in the US and Europe and expected to be on the
-
Celgene signs $500m antibody deal with Sutro
In addition, Roche is involved in the advancement of antibody-drug conjugates with T-DM1, which has caused great excitement for its potential in the treatment of breast cancer.
More from news
Approximately 4 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
An eye towards the biobetter in South Korea
It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Roche names John Reed as new head of early research
investigational medicines, such as breast cancer drug T-DM1.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- Pfizer enters late-stage haemophilia B gene therapy trial
- Porterhouse Medical strengthens the team with three new members.
- Developing advocacy in the pharmaceutical industry.
- Roche’s Tamiflu successor hits the mark in complicated flu
- Novartis launch NET cancer community app
- J&J’s Invokana aces diabetic kidney disease trial, setting up filings
PMHub
M3 (EU)
M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- ...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
